- ►fosalan.co.il [PDF] HG Bone, D Hosking, JP Devogelaer, JR … - The New England journal of medicine, 2004 - nejm.highwire.org Methods The initial three-year phase of the study compared three daily doses of
alendronate with placebo. Women in the original placebo group received
alendronate in years 4 and 5 and then were discharged. Women in the ... Cited by 488 - Related articles - BL Direct - All 10 versions
- ►einstein.br [PDF] DM Black, AV Schwartz, KE Ensrud, JA Cauley … - Jama, 2006 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context The optimal ... Cited by 166 - Related articles - BL Direct - All 9 versions
- ►temple.edu [PDF] CJ Rosen - New England Journal of Medicine, 2005 - content.nejm.org Postmenopausal osteoporosis is a common disease with a spectrum ranging from
asymptomatic bone loss to disabling hip fracture. The National Institutes of
Health consensus conference defined osteoporosis as a disease of increased ... Cited by 110 - Related articles - BL Direct - All 10 versions
E Barrett-Connor, LE Wehren, ES Siris, P … - Menopause, 2003 - journals.lww.com From the 1 University of California, San Diego, La Jolla, CA; 2 University of
Maryland, Baltimore, MD; 3 Columbia University College of Physicians and
Surgeons, New York, NY; 4 Colorado Center for Bone Research, Lakewood, CO; ... Cited by 53 - Related articles - BL Direct - All 3 versions
M McClung, R Recker, P Miller, D Fiske, J … - Bone, 2007 - Elsevier This randomized, double-blind, double-dummy, multicenter trial assessed safety
and efficacy of a single dose of IV zoledronic acid (ZOL) 5 mg vs. oral
alendronate (ALN) 70 mg weekly in postmenopausal women with low bone ... Cited by 51 - Related articles - All 6 versions
S Khosla - New England Journal of Medicine, 2003 - content.nejm.org The past 10 years have witnessed tremendous advances in our ability to treat
osteoporosis. The old mainstays of therapy, estrogen and calcitonin, have fallen
out of favor because of concern about long-term safety or lack of efficacy. ... Cited by 48 - Related articles - BL Direct - All 5 versions
J Yates, E Barrett-Connor, S Barlas, YT Chen, … - Obstetrics & Gynecology, 2004 - journals.lww.com From *Merck and Company, Inc, Upper Gwynedd, Pennsylvania; †University of
California, San Diego, La Jolla, California; ‡Colorado Center for Bone
Research, Lakewood, Colorado; and §Columbia University College of ... Cited by 44 - Related articles - All 5 versions
RD Wasnich, YZ Bagger, DJ Hosking, MR … - Menopause, 2004 - journals.lww.com From 1 Radiant Research-Honolulu, Honolulu, HI; 2 Center for Clinical and Basic
Research, Ballerup, Denmark; 3 Nottingham City Hospital, Nottingham, UK; 4
Oregon Osteoporosis Center, Portland, OR; and 5 Merck Research ... Cited by 37 - Related articles - BL Direct - All 3 versions
- ►stanford.edu [PDF] H Liu, K Michaud, S Nayak, DB Karpf, DK … - Archives of Internal Medicine, 2006 - archinte.highwire.org Methods The objective of this study was to evaluate the cost-effectiveness of
teriparatide-based strategies compared with alendronate sodium for the
first-line treatment of high-risk osteoporotic women. We developed a ... Cited by 33 - Related articles - BL Direct - All 7 versions
IR Reid - Current opinion in rheumatology, 2003 - journals.lww.com In the course of 2002, several new studies were published confirming the
efficacy of bisphosphonate drugs in fracture prevention in patients with
osteoporosis. Further evidence was provided of their long duration of ... Cited by 33 - Related articles - BL Direct - All 6 versions
